Multi-Year Global Partnership will Advance
Science on Athlete Health and Wellness
NYSE: ACB
TSX:ACB
EDMONTON, May 21, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian
company defining the future of cannabis worldwide, and
UFC®, the world's premier mixed
martial arts organization, are excited to announce an exclusive,
multi-year, multi-million dollar, global partnership that is
expected to significantly advance further clinical research on
the relationship between 100% hemp derived Cannabidiol (CBD)
products and athlete wellness and recovery, with a view to
accelerating CBD product development and education.
UFC boasts more than 300 million fans worldwide, with
programming that is broadcast to over 170 countries and
territories, in 40 different languages, to over one billion TV
households. The UFC Performance Institute, the world's first
mixed martial arts multi-disciplinary research, innovation, and
training center, opened in Las
Vegas in 2017 has served more than 400 athletes over
the past two years. The facility is a global leader in
athletic performance research and provides support and educational
services to athletes on health, well-being, nutrition, and injury
prevention.
The research will be conducted at the UFC's Performance
Institute in Las Vegas, Nevada, in
collaboration with UFC's sports performance team, as well as with
athletes who choose to participate in the studies. Clinical studies
will focus on pain management, inflammation, injury/exercise
recovery, and mental well-being. Aurora's research will be led by
Dr. Jason Dyck, Professor at the
University of Alberta and a Canada
Research Chair in Molecular Medicine. He also serves as an
indendent director on the board of Aurora Cannabis, where he
provides valuable oversight for the Company's scientific
efforts.
"Since the day we opened the Performance Institute, our primary
goal was to offer UFC athletes the best possible training,
nutrition, and recovery services," said UFC President Dana White. "This partnership with Aurora
is an extension of that goal, and we're looking forward to
collaborating with Aurora to find new ways to improve the health
and safety of athletes who compete in UFC."
Terry Booth, CEO of Aurora added,
"This global partnership places focus squarely on the health and
well-being of UFC's talented and highly trained athletes. The
Aurora-UFC research partnership creates a global platform to launch
targeted educational and awareness campaigns, while creating
numerous opportunities to accelerate our global CBD business."
About UFC®
UFC®, is the world's premier mixed
martial arts organization and the largest Pay-Per-View event
provider in the world. UFC boasts more than 300 million fans
worldwide, including 70 million social media followers across all
of its digital platforms, and its programming is broadcast in over
170 countries and territories to one billion TV households
worldwide in 40 different languages. UFC produces more than 40 live
events annually and consistently sells out some of the world's most
prestigious arenas. Since 2001, UFC has been proudly headquartered
in Las Vegas, supported by a
network of employees around the world. UFC's current roster of
athletes features more than 570 men and women representing over 55
countries. UFC FIGHT PASS®, the world's
leading digital subscription service for combat sports, delivers
exclusive live events, thousands of fights on-demand, and original
content to fans around the world. UFC was acquired in 2016 by
global sports, entertainment, and fashion leader Endeavor, along
with strategic investors Silver Lake Partners and KKR, in what is
among the largest transactions in sports history. For more
information, visit UFC.com and follow UFC at Facebook.com/UFC,
Twitter, Snapchat and Instagram: @UFC.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC
Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished
by its reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals
(OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI),
EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty
Group (private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur, and include, but are not limited to, the
completion of the clinical studies by the parties, the subject
matter of the clinical studies, and the results of such clinical
studies. These statements are only predictions. Various assumptions
were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news
release, including, but not limited to the participation of
athletes in the clinical studies. Forward-looking statements are
based on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and NewYork Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-and-ufc-join-forces-to-advance-cbd-research-education-and-product-development-300854055.html
SOURCE Aurora Cannabis Inc.